



- (51) **International Patent Classification:**
C12N 5/0783 (2010.01) A61K 35/17 (2015.01)
- (21) **International Application Number:**
PCT/US2022/077621
- (22) **International Filing Date:**
05 October 2022 (05.10.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/252,487 05 October 2021 (05.10.2021) US
- (71) **Applicant:** CYTOVIA THERAPEUTICS, LLC [US/US]; 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US).
- (72) **Inventors; and**
(71) **Applicants:** CHEN, Anping [US/US]; c/o Cytovia Therapeutics, LLC, 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US). CHANG, Hao-Ming [US/US]; c/o Cytovia Therapeutics, LLC, 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US).
- (72) **Inventor:** LI, Wei; c/o Cytovia Therapeutics, LLC, 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US).
- (74) **Agent:** ELRIFI, Ivor et al.; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

(54) **Title:** NATURAL KILLER CELLS AND METHODS OF USE THEREOF




FIG. 2A




FIG. 2B

(57) **Abstract:** The invention relates generally to populations of Natural Killer (NK) cells and methods of use thereof.

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*